Organization (Industry)
OCULAR THERAPEUTIX, INC
ClinicalTrials.gov lists OCULAR THERAPEUTIX, INC as lead sponsor of 33 trials. It has 16 active development programs and 4 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.2 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers OCULAR THERAPEUTIX, INC: 33 lead-sponsored trials and 2 legal-entity registrations.
Disease areas (16)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Dry Eye Syndromes | 9 |
| Cataract | 7 |
| Glaucoma | 7 |
| Glaucoma, Open-Angle | 4 |
| Pain | 4 |
Showing 5 of 16 disease areas.
Trials by start year as sponsor or collaborator (16)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 1 |
| 2024 | 2 |
| 2023 | 2 |
| 2022 | 3 |
| 2021 | 11 |
| 2020 | 16 |
| 2019 | 4 |
| 2018 | 2 |
| 2016 | 1 |
Showing 10 of 16 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 11 months across 25 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (16)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Ophthalmic Insert | Glaucoma, Open-Angle | Phase 3 | 1 |
| Dextenza Ophthalmic Insert | Cataract | Phase 3 | 1 |
| Prednisolone acetate ophthalmic suspension USP 1% | Cataract | Phase 3 | 1 |
| Ophthalmic Insert | Glaucoma | Phase 3 | 1 |
| OTX-DED | Dry Eye Syndromes | Phase 2 | 2 |
Showing 5 of 16 active programs.
Approved assets (4)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| DEXAMETHASONE | 7 |
| AFLIBERCEPT | 2 |
| Travoprost | 2 |
| Timolol | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 67% hit target (n=12) | 17% on time (n=12) |
Journals published in (20)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of cataract and refractive surgery | 9 |
| American journal of ophthalmology | 3 |
| Clinical ophthalmology (Auckland, N.Z.) | 3 |
| Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft | 2 |
| International ophthalmology clinics | 2 |
Showing 5 of 20 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 18 | 18 | 2025-10-28 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 51,951,000 | -265,939,000 | 197,096,000 |
| 2024 | 63,723,000 | -193,506,000 | 127,635,000 |
| 2023 | 58,443,000 | -80,736,000 | 61,055,000 |
| 2022 | 51,494,000 | -71,038,000 | 53,462,000 |
| 2021 | 43,522,000 | -6,553,000 | 50,083,000 |
| 2020 | 17,403,000 | -155,636,000 | 28,694,000 |
| 2019 | 4,227,000 | -86,372,000 | 41,091,000 |
| 2018 | 1,990,000 | -59,978,000 | 36,915,000 |
| 2017 | 1,923,000 | -63,386,000 | 30,880,000 |
| 2016 | 1,887,000 | -44,703,000 | 27,065,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (28)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-09-30 | Follow-on offering | 88,109,709 | Edgar offerings |
| 2025-09-30 | Follow-on offering | 474,999,996 | Edgar offerings |
| 2025-09-30 | Public offering | not disclosed | Sec extracted |
| 2025-06-11 | Other financing | not disclosed | Sec extracted |
| 2025-06-11 | Other financing | not disclosed | Sec extracted |
Showing 5 of 28 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 6 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Ocular Therapeutix, Inc. | Bedford, US | FDA |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (3)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Fortrea Holdings Inc. | Uses vendor | 3 |
| Massachusetts Eye and Ear Infirmary | Co sponsors trial with | 1 |
| Sight Medical Doctors PLLC | Co sponsors trial with | 1 |
Latest dated events (112)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027 H1 | PDUFA decision date | Regulatory decision dates extracted from SEC filings |
| 2026-04-27 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026 Q1 | PDUFA decision date | Regulatory decision dates extracted from SEC filings |
| 2026 Q1 | Priority review | Regulatory decision dates extracted from SEC filings |
| 2025-11-17 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 112 events.
Biomarker capability evidence (33)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AATF | Trial collaborator | Named in trial inclusion criteria |
| AATF | Trial collaborator | Named in trial inclusion criteria |
| SLC25A20 | Trial sponsor | Named in trial inclusion criteria |
| SLC25A20 | Trial sponsor | Named in trial inclusion criteria |
| SLC25A20 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 33 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, fda warning letters, fda untitled letters, fda recalls, fda import refusals, clia clinical laboratory certificates, and biomarkers this organization publishes on.